<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096277</url>
  </required_header>
  <id_info>
    <org_study_id>MHH_NPH_SS_1/2010</org_study_id>
    <secondary_id>MHH_NPH_SS_1/2010</secondary_id>
    <nct_id>NCT01096277</nct_id>
  </id_info>
  <brief_title>Vascular Effects of Sitagliptin in Diabetes Mellitus</brief_title>
  <official_title>Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucagon-like peptide 1 (GLP-1) is a 30-amino acid gut hormone secreted in a
      nutrient-dependent manner that stimulates insulin secretion and inhibits glucagon secretion
      and gastric emptying, thereby reducing postprandial glycemia.1,2 GLP-1 is derived from
      posttranslational proteolysis of preproglucagon, and its peptide sequence is identical in
      mouse, rat, and human.2,3 After secretion from enteroendocrine L cells, GLP-1(7-36) amide is
      rapidly degraded by dipeptidyl peptidase-4 (DPP-4) to its N-terminally truncated metabolite
      GLP-1(9-36), which does not interact with the known GLP-1 receptor.4,5 The diverse actions of
      GLP-1 include the proliferation, differentiation, and protection from apoptosis of pancreatic
      Î² cells and the induction of satiety. GLP-1 also improves memory and learning, stimulates
      afferent sensory nerves, and has neuroprotective functions.1,6 Furthermore, GLP-1 receptor
      agonists have been reported to have cardiac and vascular actions in rodents and humans that
      include effects on contractility, blood pressure, cardiac output,7-10 and
      cardioprotection.11-14
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the effect of a therapy with the DPP-4-inhibitor
      sitagliptin on the prognostic relevant endothelial function and endothelial progenitor cells
      in patients with type 2 diabetes mellitus.

      Primary endpoint: Endothelium-dependent vasodilation before and after treatment of patients
      with type 2 diabetes mellitus with the DPP-4-inhibitor Sitagliptin and placebo treatment
      respectively.

      Secondary endpoint: effect of sitagliptin on mobilization, NO-production and in vivo
      regenerative capacity of human endothelial progenitor cells before and after treatment of
      patients with type 2 diabetes mellitus with the DPP-4-inhibitor sitagliptin and placebo
      treatment respectively
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Before and after two week treatment</time_frame>
    <description>Effect of sitagliptin on endothelium-dependent vasodilation before and after treatment of patients with type 2 diabetes mellitus with the DPP-4-inhibitor sitagliptin and placebo treatment respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on EPCs</measure>
    <time_frame>Before and after two week treatment</time_frame>
    <description>Effect of sitagliptin on mobilization, NO-production and in vivo regenerative capacity of human endothelial progenitor cells before and after treatment of patients with type 2 diabetes mellitus with the DPP-4-inhibitor sitagliptin and placebo treatment respectively</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg sitagliptin per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo tablet per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>oral tablets 100 mg per day for two weeks</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet, one per day for two weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes mellitus

        Exclusion Criteria:

          -  Allergy to sitagliptin

          -  Treatment with PPAR-gamma agonist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sajoscha A. Sorrentino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sajoscha A. Sorrentino, MD</last_name>
    <phone>+49511532</phone>
    <phone_ext>2101</phone_ext>
    <email>sorrentino.sajoscha@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernhard M. Schmidt, MD</last_name>
    <phone>+49511532</phone>
    <phone_ext>8554</phone_ext>
    <email>schmidt.bernhard@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sajoscha A. Sorrentino, MD</last_name>
      <email>sorrentino.sajoscha@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Sajoscha A. Sorrentino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <last_update_submitted>March 30, 2010</last_update_submitted>
  <last_update_submitted_qc>March 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sajoscha A. Sorrentino, MD</name_title>
    <organization>Hannover Medical School</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

